AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02332213 — intervention group
Intervention type: PROCEDURE
Intervention: Histological evaluation of the surgery material
Description: The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
Study NCT03684031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Control Training
Description: A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
Study NCT03684031 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Control Training Program
Description: A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
Study NCT02553278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VelaShape device
Description: Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
Study NCT02553278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour I V3 device
Description: Contour I V3 device are non invasive for fat reduction.
Study NCT01084382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arthrospira platensis
Description: Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks.
Study NCT01084382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arthrospira platensis
Description: Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks.
Study NCT01631526 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
Study NCT03010982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat and [14C] Tazemetostat
Description: Tazemetostat is a selective oral small molecule inhibitor of EZH2.
Study NCT02303314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trigonella Foenum-graecum Seed Extract
Study NCT02303314 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Drug: Placebo
Study NCT03313882 — intervention group
Intervention type: OTHER
Intervention: no intervention is involved
Study NCT04914624 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ACBT training
Description: Performed 5 days before surgery and one month after surgery, twice a day.
Study NCT04914624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acpella®PEP
Description: Continuously instruct patients to perform positive expiratory pressure training 5 days before surgery and one month after surgery, twice a day.
Study NCT04914624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDP-type II external diaphragm pacemaker
Description: Use external diaphragm pacemaker to stimulate patients' diaphragms.
Study NCT01183117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SM-01
Description: SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
Study NCT01183117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: balloon angioplasty
Study NCT02740920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02740920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Study NCT03794518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone Plus dapaglifliozin
Description: Pioglitazone Plus dapaglifliozin
Study NCT03794518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (Beta blockers, ACEI, ARB, and aldosterone )
Study NCT03177382 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total neoadjuvant treatment
Description: The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
Study NCT03177382 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
Study NCT03177382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: The TME operation will be given after the end of the neoadjuvant treatment.
Study NCT03177382 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: The TME operation will be given after the end of the neoadjuvant treatment.
Study NCT03177382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Patients will receive another 6 cycles of CAPOX after TME.
Study NCT04698772 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Blinded study group will receive ketamine for pain control (0.3 mg/kg IV over 3-5 minutes)
Study NCT04698772 — intervention group
Intervention type: DRUG
Intervention: Morphine
Description: Blinded study group will receive morphine 4 mg IV push over 3-5 minutes for pain control
Study NCT03100734 — intervention group
Intervention type: BIOLOGICAL
Intervention: Benepali
Description: As specified in the treatment arm
Study NCT03100734 — intervention group
Intervention type: BIOLOGICAL
Intervention: Enbrel
Description: As specified in the treatment arm
Study NCT02790034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan low dose
Description: 2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 5 mg bid (≥13 years of age and weighing ≥25 kg). Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
Study NCT02790034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan high dose
Description: 5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg; 10 mg bid (≥13 years of age and weighing ≥25 kg) Assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients
Study NCT02790034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
Study NCT03095898 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
Study NCT03095898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
Study NCT01343095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Earplugs
Description: Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
Study NCT01343095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noise Canceling Headphones
Description: Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
Study NCT03662906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total.
Study NCT03662906 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total.
Study NCT03235479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg tablet QD
Study NCT03235479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet to match rimegepant dose QD
Study NCT00856713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single intravenous dose of 2 mg NRL972
Study NCT00346333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutein
Description: 12mg/d
Study NCT00346333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch control
Description: Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
Study NCT01269749 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: RAI treatment
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
Study NCT01269749 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATD Group
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
Study NCT03588702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF and PEMF treatment
Description: Treatment with Venus Legacy LB2 body applicator
Study NCT02281045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVODIAL dialyzer and Selectbag citrate
Description: Evodial is a trademark of Hospal-Gambro.
Study NCT02281045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
Study NCT03304366 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pentacam (scheimpflug imaging)
Description: Corneal changes including thickness, elevations....etc
Study NCT00741078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin, amlodipine
Study NCT04360057 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PMD
Description: A script used to train the physician to engage with the patient in the topic of hand hygiene compliance used on the initial visit.
Study NCT04360057 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PMDPlus
Description: A script used to train the physician to engage with the patient in the topic of hand hygiene compliance on follow up visits
Study NCT00485940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.
Study NCT00485940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d.
Study NCT00485940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT01292681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multi-modality imaging
Description: Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
Study NCT01638949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory assessment
Description: Neuropsycological tests including clinical and original tests to compare differences between each populations.
Study NCT01638949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Circulating biomarkers measure
Description: ELISA tests from blood samples to compare differences between each populations.
Study NCT01638949 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ApoE4
Description: Evaluation of apolipoprotein E polymorphism as a risk factor.
Study NCT01638949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI and PET examinations
Description: Structural and functional MRI FDG-PET to compare differences between each populations.
Study NCT03623464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile health application and Fitbit + standard of care
Description: Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
Study NCT03623464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Post-operative standard of care information
Study NCT01659164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment for adults with ADHD
Description: 14 weeks of group treatment for adults with ADHD
Study NCT01487382 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
Study NCT02780427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal dexmedetomidine
Description: Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD).
Study NCT03998436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: Galnobax-14% gel application along with Standard of Care
Study NCT03998436 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Only Standard of Care
Description: Only Standard of Care treatment
Study NCT03998436 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle gel application along with Standard of Care
Study NCT01731249 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
Study NCT01731249 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birch pollen allergen extract
Description: Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
Study NCT04375839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia implant
Description: Following standard surgical protocol, Zirconia implant will be placed in horizontally deficient ridge.
Study NCT04375839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implant
Description: Following standard surgical protocol, Titanium implant will be placed in horizontally deficient ridge.
Study NCT03274713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity.
Study NCT03274713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Description: Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
Study NCT04689100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: Monotherapy: Accelerated titration method, IV infusion QW; Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles) Combined with chemotherapy: Conventional 3 + 3 study design, IV infusion Q2W. (28-day cycles)
Study NCT04689100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: IV infusion Q2W (28-day cycles)
Study NCT02459665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence
Description: Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
Study NCT02459665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic use of metronidazole pills (500 mg)
Description: Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
Study NCT02459665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Lcr35-containing probiotic for prevention of BV recurrence
Description: Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
Study NCT04102241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg Hemay005
Description: Hemay005 is a small molecule PDE4 inhibitor.
Study NCT04102241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos are the same as drugs, but contain no Hemay005.
Study NCT04102241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos are the same as drugs, but contain no Hemay005.
Study NCT03712241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-285
Description: Topical
Study NCT03712241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Capsule
Study NCT04906317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and dezocine
Description: Midazolam (0.05 mg/kg) and dezocine(5mg) sedation during colonoscopy, targeted to a painless level
Study NCT04906317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: standard propofol (1.5mg/kg) induction during colonoscopy, targeted to a moderate sedation level
Study NCT00964288 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK1014802 low dose
Description: oral tablet